MediGene Receives Further European Patent on EndoTAG-1
Patent renews coverage and expands the protected territory
MediGene AG has obtained an extensive patent (no. 1530465) from the European Patent Office on the manufacturing process for the drug candidate EndoTAG(TM)-1. The patent protects the manufacturing process used for EndoTAG(TM)-1, including the drying step applied, products manufactured by the specified steps, products with identical properties, as well as further specified dried cationic liposomal compounds. The term of the patent "Method of producing a cationic liposomal preparation comprising a lipophilic compound" ends on June 26, 2023.
Dr. Frank Mathias, Chief Executive Officer of MediGene AG: "This new patent is extremely important for MediGene and for the commercialization of EndoTAG(TM)-1. In addition to the good patent protection which we already possess for the EndoTAG(TM) technology in general and for EndoTAG(TM)-1 in particular, the manufacturing process and the dried formulation of our drug candidate are now also patented. Overall patent protection is renewed for the product in itself, and the protected territory has been enlarged by a number of European countries. Whereas EndoTAG(TM)-1 is administered in the form of a suspension, the drug will be commercialized in the form of a dried product, so the patent represents a major progress toward our future plans for commercialization."
Other news from the department research and development
